HLX18 vs. Opdivo after surgery for solid tumors
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares two immune-boosting drugs (HLX18 and Opdivo, also called nivolumab) in patients who have had surgery to remove certain cancers—including esophageal, melanoma, or bladder cancer—with no signs of cancer remaining. The goal is to see which drug helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 and body mass index (BMI) between 18–30 kg/m²
- One of three cancer types: esophageal or gastric junction cancer (after chemoradiotherapy and surgery), melanoma stage IIB–IV (after complete surgery), or high-risk bladder cancer (after surgery)
- Complete surgical removal of the cancer (R0 resection) with no signs of cancer on imaging or physical exam within 4 weeks before starting treatment
- Good overall health and organ function; no active heart, lung, liver, kidney, or immune-system problems
- Never received nivolumab, Opdivo, or similar immune checkpoint inhibitor drugs before
- No other active cancers, no transplant history, no active infections (HIV, hepatitis B/C, or tuberculosis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
This trial tests a new experimental drug called HLX316 in people with advanced or metastatic (spread) solid cancers that have not responded to standard treatments. The drug is designed to help your immune system fight cancer cells.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
This study tests if a new drug called HLX17 works as well as the approved drug Keytruda for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see which one better controls the cancer.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 found on some cancer cells. It is for people with advanced cervical or ovarian cancer that has stopped responding to standard treatments.
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.